Seeking Alpha

Amgen (AMGN) says late-stage testing of its Aranesp drug candidate failed to meet its primary...

Amgen (AMGN) says late-stage testing of its Aranesp drug candidate failed to meet its primary endpoint of reducing deaths in heart-failure patients. The six-year trial worked with nearly 2,300 patients with symptomatic systolic heart failure and anemia by attempting to treat their anemia caused by kidney dialysis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)